No Data
No Data
Buy Rating for Quoin Pharmaceuticals: Promising Phase 3 Trials and Strong Financial Position
Quoin Pharmaceuticals | 10-K: FY2024 Annual Report
Quoin Pharmaceuticals | 8-K: Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
QUOIN PHARMACEUTICALS Earnings Results: $QNRX Reports Quarterly Earnings
Quoin Pharmaceuticals Ltd. Reports Significant Corporate Achievements and Clinical Progress in 2024
Express News | Quoin Pharmaceuticals FY 2024 GAAP EPS $(1.91) Beats $(2.10) Estimate, Quoin Had Approximately $14.1M In Cash, Cash Equivalents And Marketable That Is Expected To Fund The Company's Operations Into Q2 Of 2026